Zepbound Alternatives & Comparison

Zepbound (tirzepatide) wins on raw efficacy: SURMOUNT-5 head-to-head showed −20.2% body weight at 72 weeks vs Wegovy's −13.7% — a 6.5-percentage-point difference. Wegovy wins on cardiovascular outcomes (SELECT trial reduced MACE 20%) — Zepbound's CV outcomes trial (SURPASS-CVOT) reads out 2027. Cash price is identical at $499/mo via NovoCare and LillyDirect. Choose based on whether weight-loss magnitude or CV risk reduction matters more.

Mounjaro and Zepbound are pharmacologically identical — both are tirzepatide manufactured by Eli Lilly. The split is regulatory: Mounjaro carries the FDA label for type 2 diabetes (SURPASS program), while Zepbound carries the labels for chronic weight management (SURMOUNT-1) and obstructive sleep apnea (SURMOUNT-OSA). LillyDirect cash prices are functionally identical at $349 starter / $499 maintenance. The right brand depends on which indication your insurance will cover.

Zepbound is the better choice for most adults seeking weight loss: SURMOUNT-1 showed 20.9% body-weight reduction at 72 weeks vs Saxenda's roughly 8% in SCALE Obesity — a nearly 3x gap — and Zepbound dosing is once weekly rather than once daily. Saxenda retains two real niches: it is FDA-approved for adolescents 12 and older (Zepbound is adult-only), and its 1-day washout suits patients planning pregnancy in the near term, vs Zepbound's roughly 6-day washout. Cash access also favors Zepbound at $349-499 via LillyDirect; Saxenda has no manufacturer cash-pay program and runs around $1,400/month retail.

Zepbound (tirzepatide) is the magnitude winner — SURMOUNT-1 delivered ~22.5% TBWL at 72 weeks via a dual GIP/GLP-1 injectable, roughly double Foundayo (orforglipron) ATTAIN-1 ~11% on a once-daily oral pill. But Foundayo wins on convenience: no needles, no fasting protocol, and dose flexibility. Lilly makes both, with cash pricing similar at list. Pick Zepbound for maximal weight loss; pick Foundayo if injection or food-timing rules are deal-breakers.

For raw efficacy, Zepbound wins decisively: SURMOUNT-1 showed -20.9% body weight at 72 weeks on the 15 mg dose versus -6.1% for Contrave in COR-I at 56 weeks. Zepbound also has an FDA-approved OSA indication (SURMOUNT-OSA, 2024) that Contrave lacks. Contrave's edge is practical: it is fully oral, ~$99/month cash, and avoids GLP-1-class GI burden. Zepbound makes sense when the goal is maximum loss; Contrave fits patients who cannot inject, cannot afford GLP-1 pricing, or have appetite-driven eating.

Zepbound is roughly twice as effective for weight loss (about 20.9% at 72 weeks vs Qsymia's 10.9% at 56 weeks) and carries an OSA indication. Qsymia stays competitive because it is a once-daily oral capsule, costs ~$100-$200/mo on Qsymia Advantage (generic phentermine plus topiramate runs ~$50/mo), and works without injections. Qsymia ships with a REMS program due to topiramate teratogenicity, requires monthly pregnancy testing in people who can become pregnant, and is contraindicated in pregnancy, glaucoma, and hyperthyroidism. Zepbound wins on magnitude; Qsymia wins on access and route.